Active efflux kinetics of etoposide from rabbit small intestine and colon

Biopharmaceutics and Drug Disposition

Volumn 21, Issue 3, 2000, Pages 83-93

  Kunta, Jeevan ^a   Yan, Jiansheng ^a   Makhey, Vijaya D ^a   Sinko, Patrick J ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Efflux; Etoposide; Rabbit intestine; Saquinavir; Secretion; Verapamil

Indexed keywords

ETOPOSIDE; SAQUINAVIR; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; COLON; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DIFFUSION CHAMBER; DRUG ABSORPTION; DRUG ELIMINATION; DRUG INHIBITION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; ENERGY; FEMALE; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE SECRETION; NONHUMAN; RABBIT; SMALL INTESTINE; TEMPERATURE DEPENDENCE; TRANSPORT KINETICS;

ANIMALS; ANION TRANSPORT PROTEINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; INTESTINE, SMALL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RABBITS; TEMPERATURE;

EID: 0033646441     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-081X(200004)21:3<83::AID-BDD220>3.0.CO;2-J     Document Type: Article

References (56)

1. Etoposide (VP-16-213): Current status of an active anticancer drug
2. Etoposide for epidemic Kaposi's sarcoma: A phase II study
3. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy
4. The pharmacokinetics of oral etoposide (VP16-213)
5. Variable bioavailability following repeated oral doses of etoposide
6. Bioavailability and pharmacokinetics of etoposide (VP16)
7. Pharmacological attempts to improve the bioavailability of oral etoposide
8. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line over expressing the multidrug resistance-associated protein (MRP) gene
9. Overexpression of a transporter gene in a multidrug-resistant human long cancer cell line
10. Over expression of a M, 110000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
11. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: Pharmacokinetic and photoaffinity labeling studies
12. Over expression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs
13. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene
14. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines
15. Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines
16. Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines
17. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells
18. Molecular cloning of canalicular multi-specific organic anion transporter defective in EHBR
19. The canalicular multidrug resistance protein 'cMRP/MRP2' a novel conjugate export pump expressed in the apical membrane of hepatocytes
20. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP
21. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors
22. Permeability characteristics of various intestinal regions of rabbit, dog, and monkey
23. Mechanism of dextran transport across rabbit intestinal tissues and a human colon cell-line (Caco-2)
24. Intestinal elimination of ciprofloxacin in rabbits
25. Conductive pathways for chloride and oxalate in rabbit ileal brush-border membrane vesicles
26. Expression cloning of a mammalian proton-coupled oligopeptide transporter
27. Functional analysis of a chemeric mammalian peptide transporter derived from the intestinal and renal isoforms
28. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, noval vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, p-glycoprotein dual substrate, in male Sprague-Dawley rats
29. In vitro and in vivo drug interactions involving human CYP3A
30. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
31. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine
32. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
33. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of k(i) values and impact of CYP3A5 expression
34. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4
35. Bioavailability of low-dose oral etoposide
36. Comparison of effects of natural of artificial rodent diet on etoposide absorption in rats
37. Transport of a large neutral amino acid (phenylalanine) in a human intestinal epithelial cell line: Caco-2
38. Mechanisms to improve chemotherapy effectiveness
39. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption
40. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption
41. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organix cations across rat intestine
42. The multidrug transporter, a double-edged sword
43. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery
44. Molecular cloning and expression of a cyclic AMP-activated chloride conductance regulator: A novel ATP-binding cassette transporter
45. Relevance of P-glycoprotein for the enteral absorption of cyclosporine A: In vitro-in vivo correlation
46. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cells monolayers in the prescence of cytochrome P-450 3A-related compounds
47. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: Implications for the mechanisms of drug resistance
48. Two prolonged schedules of single agent oral etoposide of differing duration and dose in patients with untreated small cell lung cancer (SCLC)
49. Gastric emptying and drug absorption
50. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy
51. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance
52. Relationship of VP-16 to the classical multidrug resistance phenotype
53. Drug transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells
54. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2)
55. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
56. Characterization of saquinavir intestinal transport using rat jejunum and MDCKII cell monolayers over expressing P-glycoprotein, MRP (MRP1) and cMOAT (MRP2)